Neogen (NEOG) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates

Core Insights - Neogen (NEOG) reported a revenue of $225.46 million for the quarter ended May 2025, reflecting a 4.8% decline year-over-year, with EPS at $0.05 compared to $0.10 in the same quarter last year [1] - The revenue exceeded the Zacks Consensus Estimate of $221.26 million by 1.9%, while the EPS fell short of the consensus estimate of $0.08 by 37.5% [1] Revenue Breakdown - Food Safety revenues were $161.83 million, surpassing the average estimate of $155.05 million, but down 3% year-over-year [4] - Animal Safety revenues totaled $63.63 million, below the average estimate of $66.2 million, marking a 9% decline year-over-year [4] - Specific Food Safety segments showed varied performance: - Natural Toxins & Allergens: $18.58 million, slightly above the estimate of $18.35 million, down 2.9% year-over-year [4] - Indicator Testing, Culture Media & Other: $83.21 million, exceeding the estimate of $81.37 million, down 5.3% year-over-year [4] - Rodent Control, Insect Control & Disinfectants: $11.25 million, above the estimate of $10.72 million, up 4.4% year-over-year [4] - Genomics Services: $6.33 million, significantly below the estimate of $16.02 million, down 0.3% year-over-year [4] - Animal Safety segments also showed declines: - Life Sciences: $1.64 million, slightly below the estimate of $1.69 million, down 9.4% year-over-year [4] - Veterinary Instruments & Disposables: $16.26 million, below the estimate of $16.64 million, down 9.7% year-over-year [4] - Rodent Control, Insect Control & Disinfectants: $21.51 million, below the estimate of $23 million, down 6.7% year-over-year [4] - Genomics Services: $16.53 million, significantly above the estimate of $6.01 million, down 4.4% year-over-year [4] - Bacterial & General Sanitation revenues were $42.46 million, exceeding the estimate of $37.88 million, down 0.9% year-over-year [4] Stock Performance - Neogen's shares have returned -4.9% over the past month, contrasting with the Zacks S&P 500 composite's +3.4% change [3] - The stock currently holds a Zacks Rank 4 (Sell), indicating potential underperformance relative to the broader market in the near term [3]